Catalent expands Kansas City plant for Pharmacyclics commercial contract

By Dan Stanton

- Last updated on GMT

Related tags Contract

Catalent awarded commercial contract from KC, Missouri facility
Catalent awarded commercial contract from KC, Missouri facility
Catalent says it is creating dedicated space and possibly jobs at its Missouri facility in order to service a commercial contract for Pharmacyclics’ oncology drug Imbruvica.

The contract development and manufacturing organisation (CDMO) has manufactured clinical supplies of Imbruvica (Ibrutinib)on behalf of Pharmacyclics for more than three years, a company spokesman told, and following approval from the US Food and Drug Administration (FDA) earlier this month, Catalent will now provide drug product capsules for commercial supply.

The drug is manufactured from Catalent’s Kansas City, Missouri, facility acquired in 2011 from Aptuit​ and we were told as part of continued global investment the site will see the firm “building out dedicated space to accommodate the commercial volume” ​from this extended partnership.

“[Kansas City] provides a wide range of fully integrated support services from formulation development and analytical testing to clinical supply services as well as clinical and commercial manufacturing for oral dose forms,”​ we were told and “the expansion is scheduled to be completed by the middle of 2014, and Catalent will announce further details in the near future.”

The agreement was reached after the 450,000 q ft site underwent an FDA Pre-Approval Inspection that resulted in zero observations, the company said.

In a statement Heow Tan, Chief of Technical Operations at Pharmacyclics, said: “It is important that we work with a development partner with expertise in both clinical and commercial supply as well as US and worldwide GMP regulations, to ensure reliable quality supply to patients.”


“Catalent currently employs 334 workers in Kansas City,”​ was told, “and it is likely that we will increase the number of employees to accommodate this and other recently announced programmes at the site.”

Furthermore, the site has been strengthened by two other partnerships reaching regulatory approval announced in the last year. In December 2012 Exelixis’ Cometriq (cabozantinib) gained FDA approval, and a month later Aegerion’s Juxtapid (lomitapide) also got the thumbs up (and subsequently European Commission approval).

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more